Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Duration of treatment does it improve outcomes Hypomethylating agents in MD
Myelodysplastic Syndromes Published 2 years ago
Factors that influence treatment adherence and outcomes in MDS
Myelodysplastic Syndromes Published 2 years ago
Recommendations to improve Real World outcomes in MDS patients
Myelodysplastic Syndromes Published 2 years ago
Content
Myelodysplastic Syndromes
3m 14s
Low Risk MDS - Key Practice Points
Published 04 Oct 2022
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features. Current rIsk stratification IPSS-R is based on Hematological and Cytogenetic abnormalities. Recently updated stratification IPSS -M published in NEJM (2022) has integrated Molecular features with Hematologic and Cytogenetic abnormalities. IPSS-M stratifies the patients into 5 risk categories namely very low, low, moderate, high-risk groups. Implications in practice include use of supportive care as mode of treatment for very low risk patients.
